Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Medical risk factor treatment in peripheral arterial disease. Need for further improvement.

Alhadad, Alaa LU ; Wictorsson, C ; Lindblad, Bengt LU and Gottsäter, Anders LU (2013) In International Angiology 32(3). p.332-338
Abstract
Aim: Risk factors for development of peripheral arterial disease (PAD) are the same as for atherosclerotic coronary or precerebral disease, and patients with PAD have a high prevalence of concomitant atherosclerotic disease in coronary and precerebral arteries. However, these patients are still less likely to receive appropriate pharmacological secondary prevention than patients with coronary artery disease. The aim of this study was to evaluate the treatment of risk factors for patients undergoing open or endovascular surgery for PAD in our vascular department. Methods: We evaluated pharmacological treatment, lipid levels, blood pressures (BP), and smoking habits one month postoperatively in 953 patients (age [mean ± SD] 71±11 years, 524... (More)
Aim: Risk factors for development of peripheral arterial disease (PAD) are the same as for atherosclerotic coronary or precerebral disease, and patients with PAD have a high prevalence of concomitant atherosclerotic disease in coronary and precerebral arteries. However, these patients are still less likely to receive appropriate pharmacological secondary prevention than patients with coronary artery disease. The aim of this study was to evaluate the treatment of risk factors for patients undergoing open or endovascular surgery for PAD in our vascular department. Methods: We evaluated pharmacological treatment, lipid levels, blood pressures (BP), and smoking habits one month postoperatively in 953 patients (age [mean ± SD] 71±11 years, 524 [55%] men) undergoing open or endovascular surgical interventions for PAD. Results: We found that 89% of patients received statins and 98% received either platelet aggregation inhibitors or anticoagulants at the one month follow-up. Four hundred nineteen (70%) patients had achieved target level <4.5 mmol/L for s-total cholesterol, and 394 (67%) target level <2.5 mmol/L for s-LDL cholesterol. BP (mean ± SD) was 144±22/76±12 mmHg, systolic and diastolic target BPs (<140 mmHg and <90 mmHg, respectively) were achieved in 482 (51%) and 887 (95%) patients, respectively. The proportion of active smokers had been reduced from 41% preoperatively to 24% at the one month follow-up (P<0.0001). Conclusion: Even though our practice has improved, there is still room for better follow-up of pharmacological risk factor treatment in PAD patients. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Angiology
volume
32
issue
3
pages
332 - 338
publisher
Minerva Medica
external identifiers
  • wos:000322750400009
  • pmid:23711686
  • scopus:84881357856
ISSN
1827-1839
language
English
LU publication?
yes
id
439afd44-6dc3-4d47-8efe-57a93e773cfe (old id 3804091)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23711686?dopt=Abstract
date added to LUP
2016-04-01 10:43:29
date last changed
2022-03-19 23:24:43
@article{439afd44-6dc3-4d47-8efe-57a93e773cfe,
  abstract     = {{Aim: Risk factors for development of peripheral arterial disease (PAD) are the same as for atherosclerotic coronary or precerebral disease, and patients with PAD have a high prevalence of concomitant atherosclerotic disease in coronary and precerebral arteries. However, these patients are still less likely to receive appropriate pharmacological secondary prevention than patients with coronary artery disease. The aim of this study was to evaluate the treatment of risk factors for patients undergoing open or endovascular surgery for PAD in our vascular department. Methods: We evaluated pharmacological treatment, lipid levels, blood pressures (BP), and smoking habits one month postoperatively in 953 patients (age [mean ± SD] 71±11 years, 524 [55%] men) undergoing open or endovascular surgical interventions for PAD. Results: We found that 89% of patients received statins and 98% received either platelet aggregation inhibitors or anticoagulants at the one month follow-up. Four hundred nineteen (70%) patients had achieved target level &lt;4.5 mmol/L for s-total cholesterol, and 394 (67%) target level &lt;2.5 mmol/L for s-LDL cholesterol. BP (mean ± SD) was 144±22/76±12 mmHg, systolic and diastolic target BPs (&lt;140 mmHg and &lt;90 mmHg, respectively) were achieved in 482 (51%) and 887 (95%) patients, respectively. The proportion of active smokers had been reduced from 41% preoperatively to 24% at the one month follow-up (P&lt;0.0001). Conclusion: Even though our practice has improved, there is still room for better follow-up of pharmacological risk factor treatment in PAD patients.}},
  author       = {{Alhadad, Alaa and Wictorsson, C and Lindblad, Bengt and Gottsäter, Anders}},
  issn         = {{1827-1839}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{332--338}},
  publisher    = {{Minerva Medica}},
  series       = {{International Angiology}},
  title        = {{Medical risk factor treatment in peripheral arterial disease. Need for further improvement.}},
  url          = {{http://www.ncbi.nlm.nih.gov/pubmed/23711686?dopt=Abstract}},
  volume       = {{32}},
  year         = {{2013}},
}